drugset / Trial / NCT00979615

Safety and Efficacy of Olopatadine 0.6% and Azelastine 137 Mcg in Vasomotor Rhinitis

NCT00979615

Phase 4 Completed 129 enrolled Alcon Research
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to examine safety and efficacy of Patanase and Astelin in treating the symptoms of non-allergic vasomotor rhinitis (VMR).

Timeline

Start
2009-09
Primary completion
2009-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Azelastine Small molecule 137 ug Intranasal
Subject Olopatadine Other / unclassified 0.6 % Intranasal

Indications